ZEID K KAYALI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- RIALTO, CA
- NPI
- 1396777538
- Received
- $230,219 in 755 records, 2019 to 2025 ($219,776 general, $10,442 research)
- As principal investigator
- $14,009,469 of research payments to others in 2,082 records
- Source
- CMS Open Payments search ↗
On this site
- FEC donor: KAYALI, ZEID K Fuzzy (same full name with a middle name or initial, one FEC donor in that state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 132 | $50,660 |
| 2024 | General payment | 120 | $21,214 |
| 2024 | Research payment | 1 | $3,200 |
| 2023 | General payment | 141 | $24,313 |
| 2022 | General payment | 97 | $22,515 |
| 2022 | Research payment | 4 | $1,977 |
| 2021 | General payment | 89 | $16,854 |
| 2020 | General payment | 54 | $14,762 |
| 2020 | Research payment | 2 | $761 |
| 2019 | General payment | 114 | $69,456 |
| 2019 | Research payment | 1 | $4,504 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 57 | $182,671 |
| Food and Beverage | 633 | $16,517 |
| Research payment | 8 | $10,442 |
| Travel and Lodging | 47 | $9,993 |
| Honoraria | 3 | $7,190 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $3,200 |
| Consulting Fee | 1 | $150 |
| Education | 5 | $54 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-13 | Gilead Sciences, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-12 | Madrigal Pharmaceuticals | $5 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-11 | Madrigal Pharmaceuticals | $1,763 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-11 | Madrigal Pharmaceuticals | $22 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-09 | Madrigal Pharmaceuticals | $128 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-08 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-12-03 | Madrigal Pharmaceuticals | $32 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-03 | Madrigal Pharmaceuticals | $3 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-02 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-01 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-11-19 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-11-18 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-17 | Madrigal Pharmaceuticals | $42 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-12 | Alnylam Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | GIVLAARI Drug, Genetic Disease | 2025 | |
| 2025-11-11 | Gilead Sciences, Inc. | $3,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-11-10 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-11-05 | Madrigal Pharmaceuticals | $38 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-11-03 | Gilead Sciences, Inc. | $16 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-02 | Phathom Pharmaceuticals, Inc. | $34 | Food and Beverage | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-10-30 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-29 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | VELSIPITY Drug, INFLAMMATION;PAIN | 2025 | |
| 2025-10-28 | Gilead Sciences, Inc. | $124 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-10-22 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-10-21 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-21 | Madrigal Pharmaceuticals | $145 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-16 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-15 | Ipsen Biopharmaceuticals, Inc | $194 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-10-15 | Gilead Sciences, Inc. | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-09 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-10-02 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-09-30 | GENZYME CORPORATION | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-24 | Madrigal Pharmaceuticals | $44 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-09-22 | Gilead Sciences, Inc. | $144 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-22 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-09-22 | Intercept Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-09-16 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-09-16 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-09-03 | Gilead Sciences, Inc. | $6 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-27 | Madrigal Pharmaceuticals | $44 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-26 | Gilead Sciences, Inc. | $3,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-08-26 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-08-20 | Gilead Sciences, Inc. | $13 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-19 | Gilead Sciences, Inc. | $121 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-08-19 | Gilead Sciences, Inc. | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-18 | Intercept Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-08-14 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-13 | Madrigal Pharmaceuticals | $2,115 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-13 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-08-12 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-12 | Madrigal Pharmaceuticals | $140 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-11 | Madrigal Pharmaceuticals | $50 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-08-09 | Gilead Sciences, Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-08 | Gilead Sciences, Inc. | $149 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-07 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-26 | Madrigal Pharmaceuticals | $27 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-24 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-07-21 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-07-15 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-07-12 | Gilead Sciences, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-08 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-07-03 | Takeda Pharmaceuticals U.S.A., Inc. | $38 | Food and Beverage | In-kind items and services | ENTYVIO Biological, INTERNAL MEDICINE | 2025 | |
| 2025-06-24 | Madrigal Pharmaceuticals | $49 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-06-24 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-06-20 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | Intercept Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-06-14 | Gilead Sciences, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-09 | GENZYME CORPORATION | $39 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-30 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-05-28 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-05-21 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-05-20 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-20 | Madrigal Pharmaceuticals | $121 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-19 | Ipsen Biopharmaceuticals, Inc | $33 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2025 | |
| 2025-05-13 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-13 | Madrigal Pharmaceuticals | $129 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-12 | Intercept Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-05-08 | Madrigal Pharmaceuticals | $5,993 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-08 | Madrigal Pharmaceuticals | $330 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-08 | Madrigal Pharmaceuticals | $203 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-08 | Madrigal Pharmaceuticals | $141 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-08 | Madrigal Pharmaceuticals | $45 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-08 | Madrigal Pharmaceuticals | $20 | Food and Beverage | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-07 | GENZYME CORPORATION | $34 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-30 | CapsoVision, Inc. | $18 | Food and Beverage | Cash or cash equivalent | CapsoCam Plus Device, Gastroenterology | 2025 | |
| 2025-04-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-04-24 | Madrigal Pharmaceuticals | $41 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-21 | Mallinckrodt Hospital Products Inc. | $29 | Food and Beverage | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2025 | |
| 2025-04-17 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-16 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-04-16 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-04-16 | Gilead Sciences, Inc. | $2 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-15 | CapsoVision, Inc. | $16 | Food and Beverage | Cash or cash equivalent | CapsoCam Plus Device, Gastroenterology | 2025 | |
| 2025-04-10 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-09 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2025 | |
| 2025-04-08 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-04-02 | Madrigal Pharmaceuticals | $39 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-01 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-03-31 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-29 | Gilead Sciences, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-03-26 | Gilead Sciences, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-13 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-12 | Madrigal Pharmaceuticals | $2,820 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-03-11 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-03-05 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-28 | Madrigal Pharmaceuticals | $9 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-27 | Madrigal Pharmaceuticals | $1,763 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-27 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-26 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-02-21 | Madrigal Pharmaceuticals | $7 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-19 | Madrigal Pharmaceuticals | $4,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-19 | Madrigal Pharmaceuticals | $274 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-19 | Madrigal Pharmaceuticals | $167 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-19 | Madrigal Pharmaceuticals | $121 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-02-18 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-02-17 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-02-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2025-02-04 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-02-04 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-02-01 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-01-27 | Madrigal Pharmaceuticals | $48 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-01-27 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-01-24 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-01-22 | Intercept Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2025 | |
| 2025-01-22 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-01-16 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-01-09 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-01-02 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2025 | |
| 2024-12-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-12-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-12-23 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-12-16 | Madrigal Pharmaceuticals | $28 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-12-11 | Intercept Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2024 | |
| 2024-12-10 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-12-05 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-12-04 | ALBIREO PHARMA, INC. | $22 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2024 | |
| 2024-12-02 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-11-26 | Madrigal Pharmaceuticals | $48 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-11-21 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-11-19 | GENZYME CORPORATION | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-11-14 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-11-06 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-11-04 | Madrigal Pharmaceuticals | $46 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-10-23 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-10-16 | Madrigal Pharmaceuticals | $3,173 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-10-16 | Madrigal Pharmaceuticals | $144 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-10-16 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-10-15 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-10-14 | Madrigal Pharmaceuticals | $14 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-10-10 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | 2024 | |
| 2024-10-09 | Gilead Sciences, Inc. | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-04 | Celgene Corporation | $11 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-09-26 | PFIZER INC. | $3,200 | Research payment | In-kind items and services | PF07055341 CLINICAL PUBLICATION PROGRAM | 2024 | |
| 2024-09-25 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-09-24 | Madrigal Pharmaceuticals | $50 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-09-19 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-09-18 | Mirum Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | Livmarli Drug, Alagille syndrome | 2024 | |
| 2024-09-14 | Gilead Sciences, Inc. | $34 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-12 | Madrigal Pharmaceuticals | $4,583 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $329 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $250 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $142 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $24 | Travel and Lodging | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $20 | Food and Beverage | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-10 | Gilead Sciences, Inc. | $60 | Travel and Lodging | In-kind items and services | Epclusa Drug, HCV | 2024 | |
| 2024-09-10 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-09-10 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-09-04 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-09-03 | Ardelyx, Inc. | $17 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-08-29 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-08-23 | Celgene Corporation | $8 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-08-22 | Gilead Sciences, Inc. | $3,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2024 | |
| 2024-08-20 | Gilead Sciences, Inc. | $121 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2024 | |
| 2024-08-20 | ALBIREO PHARMA, INC. | $16 | Food and Beverage | In-kind items and services | IQIRVO Drug, Rare Disease | 2024 | |
| 2024-08-20 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-08-19 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-08-16 | Celgene Corporation | $18 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-08-15 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-08-09 | Gilead Sciences, Inc. | $26 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-08-08 | Gilead Sciences, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-08-07 | Celgene Corporation | $12 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2024 | |
| 2024-08-03 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-07-29 | Ardelyx, Inc. | $14 | Food and Beverage | In-kind items and services | IBSRELA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-07-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $8 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-07-29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-07-25 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-07-18 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-07-17 | ABBVIE INC. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-07-10 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-07-10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2024 | |
| 2024-07-08 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-07-03 | GENZYME CORPORATION | $20 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2024 | |
| 2024-07-02 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-07-01 | Intercept Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | OCALIVA Drug, Hepatology / Gastroenterology | 2024 | |
| 2024-07-01 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2024 | |
| 2024-06-28 | ORPHALAN INC | $28 | Food and Beverage | In-kind items and services | CUVRIOR Drug, Hepatology | 2024 |
The latest 200 records of 755.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | Inland Empire Clinical Trials, LLC | $31,605 | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficac | 2025 |
| 2025-12-22 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $2,278 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,470 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,051 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,051 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,369 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,824 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,916 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $479 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | Genentech, Inc. | INLAND EMPIRE LIVER FOUNDATION | $72,997 | Giredestrant HI | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,882 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,470 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $2,242 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,824 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,369 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,882 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,916 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-19 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $2,242 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,000 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $146 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,950 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $8,800 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $146 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $19 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,500 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $877 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $3,238 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $860 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $860 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $9,514 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $4,869 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $877 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-19 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $353 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-19 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $39 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-14 | Regeneron Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $1,241 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-11-07 | Regeneron Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $1,241 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,824 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $2,242 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $479 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $479 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,470 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,369 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,051 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,369 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $2,242 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $2,242 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,916 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,470 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,369 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $479 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,824 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,051 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,882 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,369 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,916 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $3,665 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,916 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,916 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,051 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,824 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,882 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,470 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $6,470 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,882 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $10,824 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,882 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $479 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $2,242 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-11-03 | X4 Pharmaceuticals, Inc. | INLAND EMPIRE CLINICAL TRIALS LLC | $7,051 | An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of M | 2025 |
| 2025-10-31 | Genentech, Inc. | INLAND EMPIRE LIVER FOUNDATION | $14,656 | Giredestrant HI | 2025 |
| 2025-10-30 | Eli Lilly and Company | MAINE CENTER FOR CANCER MEDICINE & | $54,597 | A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR | 2025 |
| 2025-10-29 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $650 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-29 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $3,900 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-29 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $250 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-29 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $3,850 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,942 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $3,818 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $23 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $34 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $219 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $4,869 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $39 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $474 | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of | 2025 |
| 2025-10-22 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,000 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-22 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,500 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-22 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,950 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-22 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $8,800 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,942 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,942 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,942 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $4,869 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $2,587 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | INLAND EMPIRE LIVER FOUNDATION | $1,942 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rialto, CA, county San Bernardino County, CA, state California; placed by its city name.
| Measure | Place (city or town) Rialto, CA | County San Bernardino County, CA | State California |
|---|---|---|---|
| Population B01003 | 104,143 | 2,197,104 | 39,287,377 |
| Population, 2020 census P1 | 104,026 | 2,181,654 | 39,538,223 |
| Median age B01002 | 32.6 | 34.7 | 37.9 |
| Under 18 B01001 | 26.7% | 25.5% | 22.0% |
| 65 and over B01001 | 10.8% | 12.6% | 15.7% |
| Households B11001 | 27,047 | 674,915 | 13,548,091 |
| Foreign born B05002 | 24.6% | 21.6% | 27.0% |
| Median household income B19013 | $88,857 | $85,478 | $99,122 |
| Median family income B19113 | $94,417 | $93,416 | $113,346 |
| Per capita income B19301 | $27,742 | $34,343 | $49,513 |
| Poverty rate B17001 | 12.7% | 13.3% | 12.0% |
| Unemployment rate B23025 | 7.7% | 7.1% | 6.6% |
| Civilian labor force B23025 | 51,232 | 1,046,624 | 20,068,466 |
| Mean commute (minutes) B08013 | 31.9 | 32.6 | 28.7 |
| Bachelor's degree or higher B15003 | 12.6% | 23.3% | 37.1% |
| Housing units B25001 | 27,973 | 743,886 | 14,644,735 |
| Owner-occupied B25003 | 66.2% | 62.1% | 55.9% |
| Renters B25003 | 33.8% | 37.9% | 44.1% |
| Median home value B25077 | $487,900 | $505,000 | $734,700 |
| Median gross rent B25064 | $1,759 | $1,801 | $2,036 |
| White, not Hispanic B03002 | 8.8% | 24.7% | 33.8% |
| Black B03002 | 11.3% | 7.5% | 5.2% |
| Hispanic or Latino B03002 | 74.8% | 55.2% | 40.2% |
| Asian B03002 | 2.2% | 8.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rialto, CA.
Comments